ArticleJournal of insect science (Online)2025
Oxalic acid vaporization: effectiveness against Varroa destructor (Mesostigmata: Varroidae) and safety for Apis mellifera (Hymenoptera: Apidae).
Article in Journal of insect science (Online), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Oxalic acid (OA) is a promising tool for controlling varroa mites (Varroa destructor Anderson and Trueman), a devastating pest of the European honey bee (Apis mellifera L.). Applying OA as a vapor inside honey bee colonies has been gaining popularity among beekeepers. We conducted a 2-year field study to evaluate the effectiveness of OA in controlling Varroa and assess the potential negative impacts of OA on honey bee larval development. Different doses of OA (1, 2, and 4 g in 2021; 3 and 4 g in 2022) were applied once a week over 3 wks in August at Oregon State University's apiary in Corvallis, OR. Each experimental group included 8 honey bee colonies, with control groups receiving no OA. The Varroa levels in colonies treated with 1 g OA (the current label dose in the US) and 2 g OA were not significantly different from each other and the control group. In both years, 4 g OA effectively suppressed the Varroa population growth but also appeared detrimental to the honey bee larval development. Our findings suggest that while the legally permissible dose of 1 g OA per brood chamber in the United States is insufficient for effective Varroa control, higher doses (3 and 4 g) can significantly suppress Varroa population growth but may also increase larval mortality, highlighting a trade-off between Varroa control and colony health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.